Prelude Therapeutics Incorporated
PRLD
$1.21
-$0.03-2.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.26% | -16.50% | -11.86% | 11.16% | 3.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.37% | 0.77% | 1.21% | 11.95% | 14.71% |
| Operating Income | 13.37% | -0.77% | 9.49% | -2.97% | -14.71% |
| Income Before Tax | 10.10% | -2.08% | 13.13% | -5.43% | -14.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.10% | -2.08% | 13.13% | -5.43% | -14.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.10% | -2.08% | 13.13% | -5.43% | -14.16% |
| EBIT | 13.37% | -0.77% | 9.49% | -2.97% | -14.71% |
| EBITDA | 13.49% | -0.75% | 10.00% | -2.61% | -14.31% |
| EPS Basic | 10.36% | -1.73% | 20.32% | 5.99% | 15.27% |
| Normalized Basic EPS | 10.36% | -1.73% | 20.30% | 5.98% | 15.26% |
| EPS Diluted | 10.36% | -0.52% | 20.32% | 4.97% | 15.27% |
| Normalized Diluted EPS | 10.36% | -1.73% | 20.30% | 5.98% | 15.26% |
| Average Basic Shares Outstanding | 0.31% | 0.33% | 9.02% | 12.15% | 34.71% |
| Average Diluted Shares Outstanding | 0.31% | 0.33% | 9.02% | 12.15% | 34.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |